In our research, we discovered that MIR155HG can recruit more CD8+ T cells by CCL5, both in vivo and in vitro, through immunohistochemistry and T cell recruitment assay, thereby mitigating its own cancer-promoting effects. This evidence concerns the gene CD8A and cancer.